— Potential for durable responses with alternative antigen-targeted therapy A promising new treatment targeting a different antigen has shown success among patients with large B-cell lymphoma who previously relapsed after receiving CD19-directed CAR T-cell therapy (CAR19), according to findings from a phase I dose-finding study. In the study, 38 patients who had not responded to CAR19 achieved a 68% overall response rate and a 53% complete response rate following treatment with autologous

Supporting a family member or partner with schizophrenia in staying on track with their medication and treatment plan requires a team effort. If they resist treatment at times, it’s important to try to understand their perspective. Make space to talk about their concerns, apprehensions, and frustrations—building trust is key. Work collaboratively with them and their healthcare provider to make decisions about medication. By fostering a sense of safety and open communication, you’ll help ensure